Trade name
Endoxan
Presentation and preparation
|
Vial size
(powder volume) |
Fluid to add
|
Volume to add
|
Resulting concentration
|
|---|---|---|---|
| 500 mg (negligible) |
Sodium chloride 0.9% | 25 mL | 20 mg/mL |
| 1 g (negligible) |
Sodium chloride 0.9% | 50 mL | 20 mg/mL |
| 2 g (negligible) |
Sodium chloride 0.9% | 100 mL | 20 mg/mL |
Reconstitute with sodium chloride 0.9% to 20 mg/mL for IV administration. Shake to dissolve and allow to stand until clear.
IV administration
For oncology patients, refer to local treatment protocol.
Give reconstituted solution undiluted over 3 minutes or dilute to 2 to 20 mg/mL and give over 30 to 60 minutes.
For doses greater than 1800 mg/m2, give over 4 to 6 hours.
Other routes of administration
IM: Not recommended.
SC: Not recommended.
Compatible IV fluids
Glucose 5%
Glucose 5% and sodium chloride 0.9%
Sodium chloride 0.9%
Y-site only and cyclophosphamide 8 mg/mL or weaker:
Plasma-Lyte 148
Additional information
Cytotoxic medication: refer to RCH Safe Handling of Hazardous Medicines Procedure or relevant local guideline.
Extravasation risk.
Observe closely for anaphylactic reactions.
Use only where facilities for cardiac monitoring and cardio-respiratory resuscitation exist.
Ensure adequate hydration during and after administration. Refer to relevant local guidelines.
Consider the use of antiemetics to prevent nausea and vomiting. Refer to relevant local guidelines.
Rapid administration may cause dizziness, headache and nasal congestion. Reduce rate of infusion if this occurs.
Protect from light during storage.